Literature DB >> 1710827

Recognition by class II alloreactive T cells of processed determinants from human serum proteins.

P Panina-Bordignon1, G Corradin, E Roosnek, A Sette, A Lanzavecchia.   

Abstract

Alloreactive T cells recognize a complex composed of an allogeneic major histocompatibility complex (MHC) molecule and a peptide derived from the processing of nonpolymorphic proteins. A sizable fraction of MHC class II alloreactive T cells is shown to recognize peptides derived from constitutive processing of human serum proteins. One such epitope is a fragment of human serum albumin. This epitope bound selectively to the human class II molecule DRw11 and was constitutively present on antigen-presenting cells in vivo. These data indicate that, in the case of MHC class II, peptides involved in allorecognition may originate from exogenous proteins.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1710827     DOI: 10.1126/science.1710827

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  13 in total

1.  Dual HLA class I and class II restricted recognition of alloreactive T lymphocytes mediated by a single T cell receptor complex.

Authors:  M H Heemskerk; R A de Paus; E G Lurvink; F Koning; A Mulder; R Willemze; J J van Rood; J H Falkenburg
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-29       Impact factor: 11.205

2.  Self peptide requirement for class II major histocompatibility complex allorecognition.

Authors:  S Demotz; A Sette; K Sakaguchi; R Buchner; E Appella; H M Grey
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-01       Impact factor: 11.205

Review 3.  Modulation of allergen-specific antibody responses by T-cell-based peptide vaccine(s). Principles and potential.

Authors:  S S Mohapatra
Journal:  Clin Rev Allergy       Date:  1994

4.  The I-Ab-restricted alloresponse of D10.G4.1 T cells is based on the recognition of an endogenous peptide.

Authors:  G Gradehandt; N Kleber; F Mattner; S Milbradt; E Rüde
Journal:  Immunology       Date:  1993-04       Impact factor: 7.397

5.  The effect of mutations on the alloreactive T cell receptor/peptide-MHC interface structure: a molecular dynamics study.

Authors:  Mikhail Y Wolfson; Kwangho Nam; Arup K Chakraborty
Journal:  J Phys Chem B       Date:  2011-06-09       Impact factor: 2.991

6.  High-frequency alloreactive T cells augment effector function of low-frequency CD8+ T-cell responses under CD28/CD154 blockade.

Authors:  Tamara L Floyd; Steven B Orr; Shana M Coley; Samantha S Hanna; Maylene E Wagener; Allan D Kirk; Christian P Larsen; Mandy L Ford
Journal:  Transplantation       Date:  2010-05-27       Impact factor: 4.939

7.  Invariant chain and DM edit self-peptide presentation by major histocompatibility complex (MHC) class II molecules.

Authors:  J F Katz; C Stebbins; E Appella; A J Sant
Journal:  J Exp Med       Date:  1996-11-01       Impact factor: 14.307

8.  Comprehensive analysis of human immunodeficiency virus type 1-specific CD4 responses reveals marked immunodominance of gag and nef and the presence of broadly recognized peptides.

Authors:  Daniel E Kaufmann; Paul M Bailey; John Sidney; Bradford Wagner; Philip J Norris; Mary N Johnston; Lisa A Cosimi; Marylyn M Addo; Mathias Lichterfeld; Marcus Altfeld; Nicole Frahm; Christian Brander; Alessandro Sette; Bruce D Walker; Eric S Rosenberg
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

9.  Specificity of T cells invading the skin during acute graft-vs.-host disease after semiallogeneic bone marrow transplantation.

Authors:  J Gaschet; B Mahé; N Milpied; M C Devilder; B Dréno; J D Bignon; F Davodeau; M M Hallet; M Bonneville; H Vié
Journal:  J Clin Invest       Date:  1993-01       Impact factor: 14.808

10.  The role of peptides in T cell alloreactivity is determined by self-major histocompatibility complex molecules.

Authors:  R Obst; N Netuschil; K Klopfer; S Stevanović; H G Rammensee
Journal:  J Exp Med       Date:  2000-03-06       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.